Class III · Low riskOngoing Initiated Jul 16, 2026 (2 months ago)
Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a…
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Why it was recalled
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
What was recalled
Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.
Recalling firm
Ascend Laboratories, LLC
NDC code
0904-7253-68
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0738-2026
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.